ArticleChinese medicine2025
Serum IgG N-glycans act as serum biomarkers for differentiation of cold and heat pattern in rheumatoid arthritis.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo develop and validate a panel of serum IgG N-glycan biomarkers for both the diagnosis of rheumatoid arthritis (RA) and the differentiation of Traditional Chinese Medicine (TCM) syndromes in RA patients.
methodsWe conducted a case-control study involving 105 patients meeting the 2010 American College of Rheumatology/European Alliance against Rheumatism RA classification criteria and 79 healthy controls. RA patients were classified according to TCM principles into cold and heat patterns. Serum IgG was enriched using titanium dioxide-porous graphitic carbon (TiO2-PGC) wafers and analyzed by high-performance liquid chromatography. IgG N-glycans were quantified using multiple reaction monitoring. Potential N-glycan biomarkers for RA diagnosis and TCM syndrome differentiation were identified and validated using multivariate data analysis.
resultsOrthogonal partial least squares discriminant analysis (OPLS-DA) identified 57 N-glycans (variable importance in projection > 1) that differentiated between RA cold pattern, heat pattern, and healthy controls. Through random forest machine learning and Kruskal-Wallis testing, we identified three acidic N-glycans (5_4_0_1-a, 5_4_0_2-a, and 5_4_0_2-b) as potential diagnostic biomarkers. In the training set, receiver operating characteristic analysis demonstrated that this three-N-glycan panel effectively distinguished RA patients from healthy controls (AUC 0.90), with particularly strong discrimination between RA heat pattern and healthy controls (AUC 0.99) and between RA cold pattern and healthy controls (AUC 0.84). The robust predictive performance was further validated in an independent test set. Additionally, we developed a logistic regression model for future clinical application in predicting both RA diagnosis and its heat/cold syndrome patterns.
conclusionThis glycomics-based approach identified and validated novel N-glycan biomarkers associated with both RA diagnosis and TCM syndrome differentiation. The combination of these N-glycan biomarkers and our diagnostic model offers a promising strategy for integrating modern diagnostic techniques with TCM classification in RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.